$CAPR
CAPRICOR THERAPEUTICS, INC.

2021 Form 10-K Financial Statement

#000155837022003341 Filed on March 11, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $244.9K $60.00K $310.3K
YoY Change -21.06% -72.73% -69.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.612M $1.490M $5.540M
YoY Change 37.41% 69.32% 53.89%
% of Gross Profit
Research & Development $13.60M $750.0K $8.500M
YoY Change 60.0% -9.64% 65.37%
% of Gross Profit
Depreciation & Amortization $245.7K $40.00K $143.9K
YoY Change 70.75% 0.0% -15.36%
% of Gross Profit
Operating Expenses $21.18M $2.240M $14.00M
YoY Change 51.31% 30.99% 60.19%
Operating Profit -$20.94M -$13.69M
YoY Change 52.95%
Interest Expense $57.46K $0.00 $30.00K
YoY Change 91.53% -100.0% -66.67%
% of Operating Profit
Other Income/Expense, Net $915.9K $32.94K
YoY Change 2680.32%
Pretax Income -$20.02M -$4.180M -$13.66M
YoY Change 46.58% 184.35% 78.8%
Income Tax
% Of Pretax Income
Net Earnings -$20.02M -$4.180M -$13.66M
YoY Change 46.61% 184.35% 78.76%
Net Earnings / Revenue -8175.86% -6966.67% -4401.94%
Basic Earnings Per Share -$0.87 -$0.88
Diluted Earnings Per Share -$0.87 -$204.8K -$0.88
COMMON SHARES
Basic Shares Outstanding 23.09M 15.57M
Diluted Shares Outstanding 23.09M 15.57M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.89M $32.67M $32.67M
YoY Change 6.78% 230.33% 230.33%
Cash & Equivalents $34.89M $32.70M $32.67M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $1.160M $1.010M $1.010M
YoY Change 14.85% 77.19% 77.19%
Inventory
Prepaid Expenses
Receivables $391.8K
Other Receivables $0.00
Total Short-Term Assets $36.44M $33.68M $33.68M
YoY Change 8.19% 219.52% 219.54%
LONG-TERM ASSETS
Property, Plant & Equipment $4.618M $850.8K $850.0K
YoY Change 443.25% 93.37% 93.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $275.7K $90.00K $90.00K
YoY Change 206.36% -25.0% -25.0%
Total Long-Term Assets $4.893M $941.7K $940.0K
YoY Change 420.57% 65.21% 64.91%
TOTAL ASSETS
Total Short-Term Assets $36.44M $33.68M $33.68M
Total Long-Term Assets $4.893M $941.7K $940.0K
Total Assets $41.33M $34.62M $34.62M
YoY Change 19.38% 211.6% 211.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.716M $2.720M $2.720M
YoY Change 36.61% 202.22% 202.22%
Accrued Expenses $417.6K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $250.0K $250.0K
YoY Change -100.0%
Total Short-Term Liabilities $4.133M $2.971M $2.970M
YoY Change 39.17% 230.14% 230.0%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M $3.450M $3.450M
YoY Change -2.14% 2.07% 2.07%
Other Long-Term Liabilities $2.453M
YoY Change
Total Long-Term Liabilities $5.829M $3.448M $3.450M
YoY Change 68.96% 2.0% 2.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.133M $2.971M $2.970M
Total Long-Term Liabilities $5.829M $3.448M $3.450M
Total Liabilities $9.962M $6.419M $6.420M
YoY Change 55.18% 50.33% 50.35%
SHAREHOLDERS EQUITY
Retained Earnings -$88.04M
YoY Change
Common Stock $116.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.37M $28.20M $28.20M
YoY Change
Total Liabilities & Shareholders Equity $41.33M $34.62M $34.62M
YoY Change 19.38% 211.6% 211.61%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$20.02M -$4.180M -$13.66M
YoY Change 46.61% 184.35% 78.76%
Depreciation, Depletion And Amortization $245.7K $40.00K $143.9K
YoY Change 70.75% 0.0% -15.36%
Cash From Operating Activities -$16.81M -$3.840M -$10.05M
YoY Change 67.18% 115.73% 47.43%
INVESTING ACTIVITIES
Capital Expenditures $1.196M -$290.0K $547.6K
YoY Change 118.46%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $5.990M
YoY Change -100.0% -100.0% -299.67%
Cash From Investing Activities -$1.196M -$290.0K $5.439M
YoY Change -121.99% -95.15% -281.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $20.17M $27.34M
YoY Change -26.22%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.23M 1.490M 33.38M
YoY Change -39.41% -67.68% 263.64%
NET CHANGE
Cash From Operating Activities -16.81M -3.840M -10.05M
Cash From Investing Activities -1.196M -290.0K 5.439M
Cash From Financing Activities 20.23M 1.490M 33.38M
Net Change In Cash 2.219M -2.640M 28.77M
YoY Change -92.28% -16.19% -4594.77%
FREE CASH FLOW
Cash From Operating Activities -$16.81M -$3.840M -$10.05M
Capital Expenditures $1.196M -$290.0K $547.6K
Free Cash Flow -$18.01M -$3.550M -$10.60M
YoY Change 69.83% 99.44% 55.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-34058
CY2021 dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24185001
CY2021 dei Document Type
DocumentType
10-K
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23089323
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15571056
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001133869
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24185001
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20577123
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1011209
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Local Phone Number
LocalPhoneNumber
358-3200
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
CAPR
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei City Area Code
CityAreaCode
310
CY2021 dei Auditor Firm
AuditorFirmId
468
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1159937
CY2021Q2 dei Entity Public Float
EntityPublicFloat
115331070
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24298406
CY2021 dei Auditor Name
AuditorName
Rose, Snyder & Jacobs LLP
CY2021 dei Auditor Location
AuditorLocation
Encino, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34885274
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32665874
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
391750
CY2020Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0
CY2021Q4 us-gaap Assets Current
AssetsCurrent
36436961
CY2020Q4 us-gaap Assets Current
AssetsCurrent
33677083
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1795696
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
850847
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
259682
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
257517
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2165
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2821944
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Other Assets
OtherAssets
275722
CY2020Q4 us-gaap Other Assets
OtherAssets
88701
CY2021Q4 us-gaap Assets
Assets
41330323
CY2020Q4 us-gaap Assets
Assets
34618796
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3116371
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2715621
CY2021Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
599388
CY2020Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
8972
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
246689
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
417632
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4133391
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2971282
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
71471
CY2021Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
3376259
CY2020Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
3376259
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2452707
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5828966
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3447730
CY2021Q4 us-gaap Liabilities
Liabilities
9962357
CY2020Q4 us-gaap Liabilities
Liabilities
6419012
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24185001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20577123
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
24185
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
20577
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
139404060
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
116216966
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108060279
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-88037759
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28199784
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41330323
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34618796
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
244898
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
310250
CY2021 us-gaap Revenues
Revenues
244898
CY2020 us-gaap Revenues
Revenues
310250
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13571045
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8457000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7612295
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5543221
CY2021 us-gaap Operating Expenses
OperatingExpenses
21183340
CY2020 us-gaap Operating Expenses
OperatingExpenses
14000221
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-20938442
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-13689971
CY2021 us-gaap Other Income
OtherIncome
548207
CY2021 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
57460
CY2020 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
32943
CY2021 capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
318160
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-7905
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
915922
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
32943
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20022520
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-13657028
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
757
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20022520
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13656271
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23089323
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15571056
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6839386
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27343069
CY2020 capr Stock Issued During Period Value Exercise Of Common Stock Warrants
StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
3158
CY2020 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
5685360
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1952679
CY2021 capr Increase Decrease In Prepaid And Other Current Assets
IncreaseDecreaseInPrepaidAndOtherCurrentAssets
148728
CY2020 capr Increase Decrease In Prepaid And Other Current Assets
IncreaseDecreaseInPrepaidAndOtherCurrentAssets
439827
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32403
CY2021 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
187021
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
757
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-13657028
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28199784
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20174448
CY2021 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
22430
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2965692
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28132
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20022520
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2021 us-gaap Profit Loss
ProfitLoss
-20022520
CY2020 us-gaap Profit Loss
ProfitLoss
-13657028
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-7905
CY2020 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
245697
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
143890
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2965692
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1952679
CY2021 capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
318160
CY2020 capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
0
CY2021 capr Noncash Lease Expenses
NoncashLeaseExpenses
129726
CY2020 capr Noncash Lease Expenses
NoncashLeaseExpenses
0
CY2021 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
391750
CY2020 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
-87968
CY2020 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-30907
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
400750
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1839944
CY2021 capr Increase Decrease In Accounts Payable And Accrued Liabilities Related Party
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty
590416
CY2020 capr Increase Decrease In Accounts Payable And Accrued Liabilities Related Party
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty
-13343
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-81331
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16809324
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10054810
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
6130193
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
12117000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1196286
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
547601
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1196286
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5439206
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20174448
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27343069
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
318160
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
50562
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5720921
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20225010
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33382150
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2219400
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
28766546
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32665874
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3899328
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34885274
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32665874
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020 us-gaap Interest Paid Net
InterestPaidNet
0
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</span></p>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34900000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32700000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
356997
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
CY2021 us-gaap Depreciation
Depreciation
243532
CY2020 us-gaap Depreciation
Depreciation
139560
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2552408
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1569427
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
756712
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
718580
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1795696
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
850847
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2165
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4330
CY2020 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2021 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
76100000
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13600000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8500000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20000000.0
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13700000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
757
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20022520
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-13657028
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23089323
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15571056
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23089323
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15571056
capr Commission Rate On Sale Price Per Share
CommissionRateOnSalePricePerShare
0.030
CY2020Q1 capr Class Of Warrants Or Rights Issuance Condition Minimum Beneficial Ownership Limitation Percent
ClassOfWarrantsOrRightsIssuanceConditionMinimumBeneficialOwnershipLimitationPercent
0.0499
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24185001
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7501696
CY2019Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
0.65
CY2020 capr Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
4200000
CY2020 capr Weighted Average Exercise Price Granted
WeightedAverageExercisePriceGranted
1.28
CY2020 capr Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
11575523
CY2020 capr Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
0.87
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
126173
CY2020Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.32
CY2021 capr Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
20391
CY2021 capr Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
1.10
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2021Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
126173
CY2021Q4 capr Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant
3869682
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.45
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.93
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.04
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2965692
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1952679
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
662968
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.39
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
178000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
171000
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
3793824
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.68
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1626055
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.005
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.004
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.015
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.00
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7700000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2021Q4 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
34400000
CY2021 capr Revenue From Grant
RevenueFromGrant
0
CY2013Q3 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P2Y
CY2013Q3 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2013Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P12M
CY2021Q4 capr Operating Leases Reduction In Monthly Lease Payments
OperatingLeasesReductionInMonthlyLeasePayments
5548
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M14D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0275
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
129726
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
81331
CY2021 capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
492380
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
656678
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
674931
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
693732
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
562627
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3080348
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
210009
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2870339
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
417632
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2452707
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2870339
CY2021Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
599388
CY2020Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
8972
CY2021 capr Compensation Receivable In Connection To Services To Be Provided
CompensationReceivableInConnectionToServicesToBeProvided
1700000
CY2021 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
245000
CY2020 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
120000

Files In Submission

Name View Source Status
0001558370-22-003341-index-headers.html Edgar Link pending
0001558370-22-003341-index.html Edgar Link pending
0001558370-22-003341.txt Edgar Link pending
0001558370-22-003341-xbrl.zip Edgar Link pending
capr-20211231.xsd Edgar Link pending
capr-20211231x10k.htm Edgar Link pending
capr-20211231x10k_htm.xml Edgar Link completed
capr-20211231xex10d54.htm Edgar Link pending
capr-20211231xex10d55.htm Edgar Link pending
capr-20211231xex21d1.htm Edgar Link pending
capr-20211231xex23d1.htm Edgar Link pending
capr-20211231xex31d1.htm Edgar Link pending
capr-20211231xex31d2.htm Edgar Link pending
capr-20211231xex32d1.htm Edgar Link pending
capr-20211231xex32d2.htm Edgar Link pending
capr-20211231xex4d1.htm Edgar Link pending
capr-20211231_cal.xml Edgar Link unprocessable
capr-20211231_def.xml Edgar Link unprocessable
capr-20211231_lab.xml Edgar Link unprocessable
capr-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending